Finance

Lists
Why is INTS down ५.४९%?
Dive Deeper
INTS:NASDAQ
Intensity Therapeutics Inc
US$ ३.१०
-५.४९%
(-०.१८) 1D
नोभेम्बर १२, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INTS...
Open
US$ ३.२५
High
US$ ३.३४
Low
US$ ३.१०
Mkt. cap
१.०२ करोड
Avg. vol.
१९.७४ हजार
Volume
११.०७ हजार
52-wk high
US$ १५.००
52-wk low
US$ २.८०
EPS
-US$ ४.४७
Beta
३.०१
Shares outstanding
३३.०१ लाख
No. of employees
५
Open
US$ ३.२५
High
US$ ३.३४
Low
US$ ३.१०
Mkt. cap
१.०२ करोड
Avg. vol.
१९.७४ हजार
Volume
११.०७ हजार
52-wk high
US$ १५.००
52-wk low
US$ २.८०
EPS
-US$ ४.४७
Beta
३.०१
Shares outstanding
३३.०१ लाख
No. of employees
५
News stories
From web sources and news partners
TradingView
TradingView
·
१ घण्टा पहिले
Oragenics gets until February 2028 to regain NYSE listing compliance
TV News Check
TV News Check
·
१४ मिनेट पहिले
Dow Dips 189, Nasdaq Sinks 100, S&P 500 Falls 27
Yahoo Finance
Yahoo Finance
·
१ घण्टा पहिले
S&P 500 Recovered $1 Trillion in 90 Minutes Despite Wider Market Crash
About Intensity Therapeutics Inc
CEO-
Employees५
Founded२०१२
HeadquartersShelton, कनेक्टिकट, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 1 analyst giving stock ratings to INTS in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for INTS in the last 3 months
Highest
Current US$ ३.१०
US$ ७.०० (+१२५.८१%)
Average
US$ ७.०० (+१२५.८१%)
Lowest
US$ ७.०० (+१२५.८१%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
US$ ७.००
+१२५.८%
11/06/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
US$ १५.००
+३८३.९%
08/11/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
US$ २०.००
+५४५.२%
03/30/2026
Matthew Venezia
Alliance Global Partners
Buy
Reiterated
US$ ३०.००
+८६७.७%
03/30/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१५.०२ लाख
११.९५ लाख
१८.३३ लाख
२४.२९ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१६.३८ लाख
१३.३१ लाख
१२.५१ लाख
११.९४ लाख
Operating expense
३१.४० लाख
२५.२६ लाख
३०.८४ लाख
३६.२३ लाख
Total operating expenses
३१.४० लाख
२५.२६ लाख
३०.८४ लाख
३६.२३ लाख
Operating income
-३१.४० लाख
-२५.२६ लाख
-३०.८४ लाख
-३६.२३ लाख
Other non operating income
१.०० हजार
-२.०० हजार
-
-३.०० हजार
EBT including unusual items
-३०.५१ लाख
-२४.३४ लाख
-३०.०७ लाख
-३५.४४ लाख
EBT excluding unusual items
-३०.५१ लाख
-२४.३४ लाख
-३०.०७ लाख
-३५.४४ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-३०.५१ लाख
-२४.३४ लाख
-३०.०७ लाख
-३५.४४ लाख
Net profit margin
-
-
-
-
Earnings per share
-
-०.९६
-१.११
-१.०९
Interest and investment income
८८.०० हजार
९४.०० हजार
७७.०० हजार
८२.०० हजार
Interest expense
-
-
-
-
Net interest expenses
८८.०० हजार
९४.०० हजार
७७.०० हजार
८२.०० हजार
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू